Skip to main content
OpenTrials
Completed

NCT Number: NCT00186303

Transplantation for Patients With Chronic Lymphocytic Leukemia

To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

Completed

Looking for future studies?

Notify Me

Key information

About this study

To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic leukemia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- adequate organ function

  • normal bone marrow cytogenetics Exclusion Criteria:- active CNS disease
  • For autologous patients more than 30% bone marrow involvement

Treatment and study plan

high dose chemotherapy then autologous hematopoietic cell transplant

Procedure

ablative allogeneic hematopoietic cell transplant

Procedure

Primary outcomes

  1. Efficacy

Secondary outcomes

  1. Feasibility

  2. Toxicity

  3. olymerase Chain Reaction (PCR) for minimal residual disease

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia

Important dates

Study start
1996
Primary completion
2010
Study completion
2010
First posted
Sep 16, 2005
Registry last updated
Dec 17, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.